{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:04:03Z","timestamp":1785402243184,"version":"3.56.0"},"reference-count":34,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Victor Babes University of Medicine and Pharmacy"},{"id":[{"id":"https:\/\/ror.org\/0391j1294","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Sobi Romania","award":["SOOS.CEE.RO_SCPP_MS.251671"],"award-info":[{"award-number":["SOOS.CEE.RO_SCPP_MS.251671"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Background\/Objectives: Carbapenem-resistant Gram-negative (CR-GN) infections are associated with high mortality in intensive care units (ICUs), with limited therapeutic options. We aimed to evaluate microbiological and clinical outcomes associated with cefiderocol in critically ill patients with multidrug-resistant (MDR) Gram-negative infections. Methods: This retrospective, single-center case series included 25 critically ill patients with carbapenem-resistant or multidrug-resistant Gram-negative infections treated with cefiderocol between May 2024 and October 2025 in a mixed ICU of a tertiary hospital in Romania. Microbiological cure was defined as eradication of the designated target pathogen at the end of therapy. Clinical evolution was assessed using the Acute Physiology and Chronic Health Evaluation II (APACHE II) and Sequential Organ Failure Assessment (SOFA) scores, as well as inflammatory biomarkers including white blood cell count (WBC), C-reactive protein (CRP), and procalcitonin (PCT). Results: Klebsiella pneumoniae was the predominant pathogen, identified in 23 of 25 patients (92%), followed by Acinetobacter baumannii (11\/25, 44%) and Pseudomonas aeruginosa (6\/25, 24%). As multiple pathogens were co-isolated in 16 patients (64%), percentages exceed 100% and are reported as proportions of patients rather than of total isolates. Microbiological cure was achieved in 68% of patients. Mortality was markedly higher in patients without microbiological eradication (88% vs. 35%). Higher baseline APACHE II (HR 1.18, 95% CI 1.02\u20131.37) and SOFA scores (HR 1.33, 95% CI 1.07\u20131.65) were associated with increased mortality. Early initiation of cefiderocol (\u226410 days from ICU admission) was associated with improved microbiological and clinical outcomes compared to delayed treatment. Reductions in severity scores and inflammatory markers, including C-reactive protein (CRP) and procalcitonin (PCT), were observed during therapy. Pathogen type and combination therapy were not clearly associated with outcomes in this cohort. Conclusions: Cefiderocol was observed in association with clinically relevant rates of microbiological eradication and improvements in clinical parameters in critically ill patients with MDR Gram-negative infections. Outcomes appeared to be primarily determined by baseline disease severity, while earlier initiation of therapy was associated with more favourable microbiological and clinical outcomes, although causality cannot be established given the observational design and absence of a comparator group. These findings are hypothesis-generating and supportive of a potential role for cefiderocol as a salvage option in high-risk ICU populations, pending validation in larger, prospective, controlled studies.<\/jats:p>","DOI":"10.3390\/pathogens15080786","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T13:53:26Z","timestamp":1784901206000},"page":"786","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Use of Cefiderocol for Multidrug-Resistant Gram-Negative Infections in Critically Ill ICU Patients: A Single-Center Case Series"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8751-6813","authenticated-orcid":false,"given":"Stelian Adrian","family":"Ritiu","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania"},{"name":"Clinic of Anaesthesia and Intensive Care, Emergency County Hospital Pius Brinzeu, 300723 Timisoara, Romania"},{"name":"Doctoral School, Victor Babes University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania"},{"name":"Anaesthesia and Intensive Care Research Center (CCATITM), Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adelina","family":"Baloi","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania"},{"name":"Clinic of Anaesthesia and Intensive Care, Emergency County Hospital Pius Brinzeu, 300723 Timisoara, Romania"},{"name":"Doctoral School, Victor Babes University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania"},{"name":"Anaesthesia and Intensive Care Research Center (CCATITM), Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4065-3650","authenticated-orcid":false,"given":"Marius","family":"P\u0103puric\u0103","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania"},{"name":"Clinic of Anaesthesia and Intensive Care, Emergency County Hospital Pius Brinzeu, 300723 Timisoara, Romania"},{"name":"Anaesthesia and Intensive Care Research Center (CCATITM), Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorel","family":"Sandesc","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania"},{"name":"Clinic of Anaesthesia and Intensive Care, Emergency County Hospital Pius Brinzeu, 300723 Timisoara, Romania"},{"name":"Anaesthesia and Intensive Care Research Center (CCATITM), Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1034-923X","authenticated-orcid":false,"given":"Daiana","family":"Toma","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania"},{"name":"Clinic of Anaesthesia and Intensive Care, Emergency County Hospital Pius Brinzeu, 300723 Timisoara, Romania"},{"name":"Doctoral School, Victor Babes University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania"},{"name":"Anaesthesia and Intensive Care Research Center (CCATITM), Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7591-7241","authenticated-orcid":false,"given":"Claudiu Rafael","family":"B\u00e2rsac","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania"},{"name":"Clinic of Anaesthesia and Intensive Care, Emergency County Hospital Pius Brinzeu, 300723 Timisoara, Romania"},{"name":"Doctoral School, Victor Babes University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania"},{"name":"Anaesthesia and Intensive Care Research Center (CCATITM), Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5195-3993","authenticated-orcid":false,"given":"Sonia Elena","family":"Popovici","sequence":"additional","affiliation":[{"name":"Doctoral School, Victor Babes University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania"},{"name":"Anaesthesia and Intensive Care Research Center (CCATITM), Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madalina","family":"Buta\u0219","sequence":"additional","affiliation":[{"name":"Doctoral School, Victor Babes University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania"},{"name":"Anaesthesia and Intensive Care Research Center (CCATITM), Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana-Maria-Ionela","family":"Botoaca","sequence":"additional","affiliation":[{"name":"Clinic of Anaesthesia and Intensive Care, Emergency County Hospital Pius Brinzeu, 300723 Timisoara, Romania"},{"name":"Anaesthesia and Intensive Care Research Center (CCATITM), Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3432-9168","authenticated-orcid":false,"given":"Ovidiu","family":"Bedreag","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania"},{"name":"Clinic of Anaesthesia and Intensive Care, Emergency County Hospital Pius Brinzeu, 300723 Timisoara, Romania"},{"name":"Anaesthesia and Intensive Care Research Center (CCATITM), Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global Burden of Bacterial Antimicrobial Resistance in 2019: A Systematic Analysis","volume":"399","author":"Murray","year":"2022","journal-title":"Lancet"},{"key":"ref_2","unstructured":"European Centre for Disease Prevention and Control, and World Health Organization (2023). Antimicrobial Resistance Surveillance in Europe 2023\u20132021 Data, WHO."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13054-025-05266-1","article-title":"Incidence of Hospital-Acquired Infections Due to Carbapenem-Resistant Enterobacterales and Pseudomonas Aeruginosa in Critically Ill Patients in Italy: A Multicentre Prospective Cohort Study","volume":"29","author":"Cortegiani","year":"2025","journal-title":"Crit. Care"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Golli, A.-L., Zlatian, O.M., Popa, S.-G., Turcu, F.L., and Balasoiu, A.T. (2025). Trends in the Antimicrobial Resistance Pattern of Bacterial Gram-Negative Pathogens in Elderly Patients Admitted to the Intensive Care Unit. Microorganisms, 13.","DOI":"10.3390\/microorganisms13102330"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Bereanu, A.-S., Bereanu, R., Mohor, C., Vintil\u0103, B.I., Codru, I.R., Olteanu, C., and Sava, M. (2024). Prevalence of Infections and Antimicrobial Resistance of ESKAPE Group Bacteria Isolated from Patients Admitted to the Intensive Care Unit of a County Emergency Hospital in Romania. Antibiotics, 13.","DOI":"10.3390\/antibiotics13050400"},{"key":"ref_6","unstructured":"World Health Organization (2024). WHO Bacterial Priority Pathogens List 2024: Bacterial Pathogens of Public Health Importance, to Guide Research, Development, and Strategies to Prevent and Control Antimicrobial Resistance, World Health Organization. [1st ed.]."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-Resistant, Extensively Drug-Resistant and Pandrug-Resistant Bacteria: An International Expert Proposal for Interim Standard Definitions for Acquired Resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s40121-025-01147-w","article-title":"From Clinical Trials to Real-World Experiences: Evidence About Cefiderocol Use and Potential Role in Empirical Therapy","volume":"14","author":"Russo","year":"2025","journal-title":"Infect. Dis. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"7396","DOI":"10.1128\/AAC.01405-16","article-title":"Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity against Pseudomonas Aeruginosa","volume":"60","author":"Ito","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S552","DOI":"10.1093\/cid\/ciz828","article-title":"Pharmacokinetic and Pharmacodynamic Profiles of Cefiderocol, a Novel Siderophore Cephalosporin","volume":"69","author":"Katsube","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e01968-17","DOI":"10.1128\/AAC.01968-17","article-title":"In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016","volume":"62","author":"Hackel","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S1473-3099(18)30554-1","article-title":"Cefiderocol versus Imipenem-Cilastatin for the Treatment of Complicated Urinary Tract Infections Caused by Gram-Negative Uropathogens: A Phase 2, Randomised, Double-Blind, Non-Inferiority Trial","volume":"18","author":"Portsmouth","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and Safety of Cefiderocol or Best Available Therapy for the Treatment of Serious Infections Caused by Carbapenem-Resistant Gram-Negative Bacteria (CREDIBLE-CR): A Randomised, Open-Label, Multicentre, Pathogen-Focused, Descriptive, Phase 3 Trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_14","first-page":"CD003344","article-title":"Beta Lactam Antibiotic Monotherapy versus Beta Lactam-Aminoglycoside Antibiotic Combination Therapy for Sepsis","volume":"2014","author":"Paul","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Piotrowski, M., Alekseeva, I., Arnet, U., and Y\u00fccel, E. (2024). Insights into the Rising Threat of Carbapenem-Resistant Enterobacterales and Pseudomonas Aeruginosa Epidemic Infections in Eastern Europe: A Systematic Literature Review. Antibiotics, 13.","DOI":"10.3390\/antibiotics13100978"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Guidelines for the Treatment of Infections Caused by Multidrug-Resistant Gram-Negative Bacilli (Endorsed by European Society of Intensive Care Medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e01009-23","DOI":"10.1128\/aac.01009-23","article-title":"The Emergence of Cefiderocol Resistance in Pseudomonas Aeruginosa from a Heteroresistant Isolate during Prolonged Therapy","volume":"68","author":"Teran","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Karakonstantis, S., Rousaki, M., and Kritsotakis, E.I. (2022). Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance. Antibiotics, 11.","DOI":"10.3390\/antibiotics11060723"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"101034","DOI":"10.1016\/j.drup.2023.101034","article-title":"Cefiderocol: Clinical Application and Emergence of Resistance","volume":"72","author":"Wang","year":"2024","journal-title":"Drug Resist. Updat."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Baicus, A., Sisu, V.D., Tatar, A.D., Gherghel, A., Iacob, D.G., Pop, C.S., and Cirstoiu, C.F. (2025). In Vitro Activity of Cefiderocol Against Multi-Drug-Resistant Gram-Negative Clinical Isolates in Romania. Antibiotics, 14.","DOI":"10.3390\/antibiotics14111113"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1093\/cid\/ciw829","article-title":"Gram-Negative Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group","volume":"64","author":"Doi","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus High-Dose, Extended-Infusion Meropenem for the Treatment of Gram-Negative Nosocomial Pneumonia (APEKS-NP): A Randomised, Double-Blind, Phase 3, Non-Inferiority Trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/cid\/ciac268","article-title":"Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum \u03b2-Lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas Aeruginosa with Difficult-to-Treat Resistance (DTR-P. Aeruginosa)","volume":"75","author":"Tamma","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e01724-22","DOI":"10.1128\/spectrum.01724-22","article-title":"In Vitro Activity of Cefiderocol against Extensively Drug-Resistant Pseudomonas Aeruginosa: CANWARD, 2007 to 2019","volume":"10","author":"Karlowsky","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Palermo, G., Medaglia, A.A., Pipit\u00f2, L., Rubino, R., Costantini, M., Accomando, S., Giammanco, G.M., and Cascio, A. (2023). Cefiderocol Efficacy in a Real-Life Setting: Single-Centre Retrospective Study. Antibiotics, 12.","DOI":"10.3390\/antibiotics12040746"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"ofad627","DOI":"10.1093\/ofid\/ofad627","article-title":"Real-Life Data on Cefiderocol Efficacy and Safety to Treat Multidrug-Resistant Acinetobacter Baumannii Infections","volume":"10","author":"Campogiani","year":"2023","journal-title":"Open Forum Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3892\/br.2025.2034","article-title":"Real-world Effectiveness and Safety of Cefiderocol in Critically Ill Patients with MDR Gram-negative Infections: Results from a Retrospective Study","volume":"23","author":"Marino","year":"2025","journal-title":"Biomed. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"28","DOI":"10.37201\/req\/s02.04.2022","article-title":"Pharmacokinetics\/Pharmacodynamics and Tolerability of Cefiderocol in the Clinical Setting","volume":"35","year":"2022","journal-title":"Rev. Esp. Quimioter."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"108305","DOI":"10.1016\/j.ijid.2025.108305","article-title":"Real-World Use of Cefiderocol as Monotherapy or Combination Therapy for the Treatment of Gram-Negative Bacterial Infections: The Multicentre Retrospective CEFI-BAC Study","volume":"163","author":"Augello","year":"2026","journal-title":"Int. J. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13613-023-01146-5","article-title":"Treatment of Critically Ill Patients with Cefiderocol for Infections Caused by Multidrug-Resistant Pathogens: Review of the Evidence","volume":"13","author":"Viale","year":"2023","journal-title":"Ann. Intensive Care"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Lewis, R.E., Palombo, M., Diani, E., Secci, B., Gibellini, D., and Gaibani, P. (2024). Synergistic Activity of Cefiderocol in Combination with Avibactam, Sulbactam or Tazobactam against Carbapenem-Resistant Gram-Negative Bacteria. Cells, 13.","DOI":"10.3390\/cells13161315"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Bavaro, D.F., Belati, A., Diella, L., Stufano, M., Romanelli, F., Scalone, L., Stolfa, S., Ronga, L., Maurmo, L., and Dell\u2019Aera, M. (2021). Cefiderocol-Based Combination Therapy for \u201cDifficult-to-Treat\u201d Gram-Negative Severe Infections: Real-Life Case Series and Future Perspectives. Antibiotics, 10.","DOI":"10.3390\/antibiotics10060652"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"106113","DOI":"10.1016\/j.jinf.2024.01.012","article-title":"Cefiderocol Either in Monotherapy or Combination versus Best Available Therapy in the Treatment of Carbapenem-Resistant Acinetobacter Baumannii Infections: A Systematic Review and Meta-Analysis","volume":"88","author":"Onorato","year":"2024","journal-title":"J. Infect."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"209","DOI":"10.18683\/germs.2025.1468","article-title":"One-Year Surveillance of Last-Resort Antimicrobial Resistance Patterns in Carbapenemase-Producing Klebsiella Pneumoniae Strains Isolated in a Romanian Tertiary Care Hospital: A Prospective Study","volume":"15","author":"Dan","year":"2025","journal-title":"Germs"}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/15\/8\/786\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T16:23:11Z","timestamp":1785169391000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/15\/8\/786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":34,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["pathogens15080786"],"URL":"https:\/\/doi.org\/10.3390\/pathogens15080786","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]}}}